Dynamic Shuttling of Nuclear Factor κB between the Nucleus and Cytoplasm as a Consequence of Inhibitor Dissociation*

Franco Carlotti‡, Steven K. Dower‡, and Eva E. Qwarnström†‡§¶

From the ‡Functional Genomics Group, Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, University of Sheffield, Glossop Road, Sheffield S10 2JF, United Kingdom and the §Department of Pathology, University of Washington, Seattle, Washington 98195-7470

© 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

Activation of the nuclear factor κB (NFκB) transcription factor is intimately associated with its translocation from the cytoplasm to the nucleus. Using the nuclear export inhibitor leptomycin B, we demonstrate shuttling of the RELA subunit of NFκB and the inhibitory subunit IκBα between these two compartments in unstimulated cells. Determination of the kinetics of nuclear entry shows marked differences for the two components; the entry of IκBα occurs more rapidly than RELA. The shuttling is suggested to be a consequence of the cytoplasmic dissociation of the NFκB-IκB complex rather than its direct nuclear import or degradation and resynthesis of IκBα. Using previously published kinetic data, this proposition is born out by the deduction that 17% of NFκB is not complexed to IκBα in a resting cell. A numerical model is presented to validate the proposed regulation of NFκB subcellular localization consequent in part on the nuclear export function and in part on the cytoplasmic retention function of IκBα. We suggest that the non-saturated interaction of NFκB with the inhibitor may enhance the specificity of action of IκB proteins on different NFκB dimers and allow additional modes of regulation of IκB function.

NFκB is a central mediator of immune and inflammatory responses. It consists of homo- or heterodimers of a family of at least five related proteins characterized by the rel homology domain (1, 2). The known members of this family are c-REL, RELA, RELB, p50, and p52. Homodimers of p50 and p52 are generally considered to be inhibitory, because they lack activation domains, but they may be converted to activators by association with the Bcl3 protein (3, 4). NFκB is regulated by a family of at least seven inhibitory proteins, IκB, characterized by multiple ankyrin-type repeats (5). The expression of both NFκB and IκB proteins is cell type- and developmental stage-specific (2). In non-lymphomyeloid cells, the most prevalent NFκB species are RELA-p50 heterodimers and p50 homodimers.

The current model for NFκB function postulates that the transcription factor is anchored in the cytoplasm by association with the inhibitor in unstimulated cells (6). Whereas both NFκB and IκB have nuclear localization signals, resulting in import of the free factors to the nucleus, these are mutually masked within the complex to abolish their nuclear import functions (7). A diverse range of stimuli, including inflammatory cytokines, bacterial lipopolysaccharide, and phorbol esters (8–10), result in the serine phosphorylation of IκBα and its subsequent degradation (11, 12). Translocation of the free transcription factor to the nucleus and activation of genes bearing cognate binding sites ensues. Tyrosine phosphorylation of IκBα, without subsequent degradation, has also been reported to release active NFκB into the nucleus (13). In addition to nuclear translocation, phosphorylation of NFκB may be important for its full activation (14–17). This phosphorylation may be induced by parallel pathways initiated by the same stimulus as that causing IκB degradation.

We have previously developed quantitative green fluorescent protein-based assays to determine the activation of NFκB in single, living cells (18). These experiments demonstrated activation by IL-1 to be dependent on the level of NFκB expression. In particular, as the expression level of NFκB increased, its rate of nuclear translocation saturated at approximately 60 molecules per s. The location of the rate-limiting step was proposed to lie within the signal transduction cascade. In this paper, we examine how the kinetics of activation are modified when nuclear export of NFκB/IκBα is blocked using the specific inhibitor of CRM1-dependent nuclear export leptomycin B (LMB) (19, 20). These data demonstrate a greater importance for nuclear export function of IκBα in maintaining a low basal activity of nuclear NFκB than has previously been supposed. We have developed a numerical model to test this mechanism of NFκB regulation against our observations.

EXPERIMENTAL PROCEDURES

Plasmids pEGFP-RELA (18), pECFP-RELA, pIκBαEGFP, and pIκBαEYFP elsewhere described. pCMV-RELA was constructed by digesting the plasmid pEGFP-RELA with HindIII plus Nhel, infilling with Klenow polymerase, and then religating. Interleukin 1β was a gift of the Immunex Corporation, and LMB was a gift of Dr. Minoru Yoshida. Cycloheximide was obtained from Sigma, and MG132 was from Calbiochem.

Cell Culture—Monkey arterial smooth muscle cells were maintained in Dulbecco’s modified Eagle’s medium (Life Technologies, Inc.) containing 10% fetal calf serum (Life Technologies, Inc.) and used between transfers 9 and 13. For microscopic assays, 20,000 cells were plated in four-chamber coverslips (NUNC) 2 days prior to transfection with 2 μg of plasmid DNA by calcium phosphate co-precipitation as described previously (18). For studies involving IκBαEGFP, the plasmid was co-transfected with pCMV-RELA to achieve cytoplasmic localization. Co-transfection of IκBα with EGFP-RELA was not necessary because EGFP-RELA induces expression of the endogenous IκBα gene (21, 22). For the ECFP-RELA/IκBαEYFP cotransfection studies, the plasmid

* This work was funded by the British Heart Foundation. The confocal microscopy facility was co-funded by the Wellcome Trust and the Medical Research Council. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡To whom correspondence should be addressed. Tel.: 44-114-271-3181; Fax: 44-114-271-3846; E-mail: E.Qwarnstrom@Sheffield.ac.uk.

The abbreviations used are: NFκB, nuclear factor κB; IκB, inhibitor of κB; IL, interleukin; LMB, leptomycin B; EGFP, enhanced green fluorescent protein; ECFP, enhanced cyan fluorescent protein; EYFP, enhanced yellow fluorescent protein.

¶Received for publication, July 13, 2000, and in revised form, September 27, 2000.

§Published, JBC Papers in Press, October 6, 2000, DOI 10.1074/jbc.M006179200

This paper is available on line at http://www.jbc.org
Dynamic Shuttling of NFkB

10294

ratio was varied from 1.1 to 1.4 to allow the analysis of cells with high concentrations of free IxB-EYFP. Analysis of IL-1/MB stimulation of IL-6 production was performed on cells plated in 24-well tissue culture dishes (75% confluent, plated 48 h prior to stimulation). The concentration of IL-6 in the supernatant was determined at the end point by enzyme-linked immunosorbent assay (Quantikine, R&D Systems Inc.).

Microscopy—EGFP-RELA and IxB-EYFP were visualized using a Molecular Dynamics confocal laser scanning microscope with a 37°C stage incubator. The images were analyzed as described previously (18) to yield parameter values as described below. The microscopy was performed with standardized laser power (10 mW) and multiphoton illumination (1067 V) settings but variable attenuation of the incident laser beam to allow on-scale recordings of both bright and faintly fluorescent cells. Fluorescence units are defined as the pixel density of the image divided by the percentage attenuation of the incident laser illumination and as such are directly proportional to EGFP fusion protein concentration. The nuclear import rate is defined as the absolute rate of increase in nuclear fluorescence during the approximately linear phase (i.e., exclusive of the initial lag and later plateau stages). The relative nuclear import rate is defined as the nuclear import rate divided by the initial cytoplasmic fluorescence; the advantage of this measure is that it is independent of the expression level when the EGFP fusion is expressed at levels that do not perturb the endogenous system. The final measurement that we use is relative fluorescent units when presenting time courses. These are calculated by dividing each measurement for a single cell by the initial cytoplasmic fluorescence of that cell and then averaging the values for the group of cells. This method has the advantages that the cells are equally weighted in the final curve and that meaningful standard deviations can be calculated. ECFP-RELA and IxB-EYFP were visualized using a C4743-95-12-bit Hamamatsu digital camera driven by OpenLab software (Improvision) with the specific filter sets XP114 and XP104 (Omega Optical). Note that the fluorescent units for these proteins are not identical with those obtained for EGFP, because their excitation/detection characteristics differ.

Modelling—Numerical modelling was performed using an iterative model developed in the Microsoft EXCEL VBA programming language (available on request). For simplicity, the model treats NFkB and IxB as a single species partitioning between nuclear and cytoplasmic compartments. All parameter values are entered at run time using a simple user interface. Initial parameter values were estimated according to our data and previous reports as follows. To assign NFkB concentrations, we used our previous estimate for the concentration of RELA at 60,000 molecules per cell. Because the levels of IxB are regulated by free NFkB, IxB is assumed to be present in 10% excess relative to NFkB. We use the dissociation constant (Kd) for the interaction of the p50/RELA dimer with IxB (3 nm (23)) because this is the highest affinity complex and is likely to be predominant in smooth muscle cells. The ratio of import/export rates (hi/hexp) for IxB was taken to be 2, because on gross overexpression of IxB-EYFP, when it is likely to be present largely free of NFkB, it partitions with a 2:1 nuclear:cytoplasmic ratio. Because grossly overexpressed ECFP-RELA is substantially nuclear, the ratio of hhi/hexp for NFkB was taken to be 50. For assignment of absolute import and export rates, we have used km and kd values for the NFkB/IxB complex of 18,400,000 m−1 min−1 and 0.055 min−1, respectively (23), which constrains the nuclear import rates for consistency with the observed resting partitioning of NFkB/IxB and their rates of nuclear import following LMB treatment (these rates are determined by running the model). For the purpose of testing the model, we have assumed that the direct import of NFkB/IxB into the nucleus is not significant.

RESULTS

We have previously reported that IL-1-stimulated nuclear translocation of EGFP-RELA is impaired at high expression levels (18). This impairment might be caused by overexpression or rapid resynthesis of IxB in the transfected cells, saturation of the nuclear import machinery, or kinetic limitations of the signal transduction pathway. To explore these possibilities, we have investigated the consequences for IL-1-induced import of blocking the nuclear export pathway with the specific inhibitor LMB. Treatment of cells with LMB alone resulted in the nuclear accumulation of EGFP-RELA (Fig. 1A), which indicates that, even in resting cells, EGFP-RELA cycles between the cytoplasm and nucleus. The rate of LMB-induced nuclear translocation of EGFP-RELA is lower than that induced by IL-1 in cells expressing physiological levels of the fusion protein. Furthermore, whereas the LMB-induced translocation is almost linear during the first 60 min of treatment (Fig. 1B) and displays minimal lag time, the IL-1-induced response has a distinct lag phase and attains a plateau. The time course of nuclear translocation in cells treated with both IL-1 and LMB also shows a plateau but at a level (6-fold above the initial cytoplasmic concentration) that is much lower than that for LMB and IL-1 alone (1.3× at 60 min and 2.5×, respectively). This level of nuclear translocation deploys approximately 70% of cytoplasmic EGFP-RELA.

To clarify the difference in response to IL-1 and LMB, we determined how the rate of nuclear translocation in individual cells varies according to the expression level of EGFP-RELA (Fig. 1C). Whereas the response to IL-1 saturates, the response to LMB is approximately linear with respect to the EGFP-RELA expression level. The maximum absolute translocation rate in response to LMB is higher than that of IL-1-stimulated cells, indicating that the limiting factor in the latter is the not the import apparatus. Furthermore, the effects of IL-1 plus LMB are clearly greater than additive, indicating increased nuclear to cytoplasmic transport of EGFP-RELA following IL-1 stimulation. However, blocking the nuclear export pathway does not significantly reduce the saturability of IL-1-induced nuclear translocation of EGFP-RELA at high expression levels (Fig. 1D), suggesting that the restriction is within the signal transduction pathway.

To further analyze the response to LMB, we have determined its effects on the inhibitory protein IxB. Treatment of cells with LMB induces the nuclear translocation of IxB-EYFP (Fig. 2A). This is in contrast to IL-1, which induces its degradation (data not shown). However, the time dependence of IxB-EYFP translocation is distinct from that for EGFP-RELA (Fig. 2B); it is more rapid and distinctly nonlinear. The concentration dependence of translocation is also moderately nonlinear, being reduced in cells expressing the highest levels (Fig. 2, C and D). However, this nonlinearity is only evident in cells with translocation rates above 0.5, rates that are not attained in the EGFP-RELA-transfected cells; so it is possible that a similar nonlinearity may in principle apply for EGFP-RELA translocation. (We cannot analyze cells with higher levels of EGFP-RELA expression because these display constitutive nuclear localization.)

The nuclear translocation of NFkB is intimately linked with activation of responsive genes. However, in contrast to the effects of LMB, stimuli that activate NFkB generally do so as a consequence of degradation of IxB. Therefore, we have investigated whether the nuclear translocation induced by LMB results in activation of NFkB, using production of the NFkB-responsive cytokine IL-6 as a reporter. We find that whereas treatment with IL-1 results in marked increase of IL-6 production, there is no change following treatment with LMB (Fig. 3). Although treatment with IL-1 and LMB together results in enhanced translocation of NFkB as compared with treatment with IL-1 alone, it yields reduced activation, presumably because nuclear NFkB/IxB complexes are less susceptible to degradation than those in the cytoplasm. Thus, although LMB induces the nuclear accumulation of NFkB, this is in an inactive form.

In considering the effects of LMB, we suggest that the data can be accounted for by three types of mechanism (Fig. 4). First, IxB and NFkB might enter the nucleus as a complex. Second, IxB and NFkB might dissociate within the cytoplasm, thereby exposing their nuclear import signals, be imported to the nucleus independently, and then reassociate. Finally, degradation of IxB may liberate free NFkB, which translocates...
into the nucleus, where it associates with newly synthesized IkB. We designed the following experiments to distinguish between these mechanisms.

Upon IL-1 stimulation, IkB is degraded by a proteasome-dependent pathway that is sensitive to the inhibitor MG132. To determine whether low intensity basal activation of this pathway is responsible for the shuttling of RELA and IkB, cells were treated with LMB and IL-1 in the presence of MG132 (Fig. 5, A and B). The degradation of IkBα and translocation of RELA in response to IL-1 are blocked by MG132, but their shuttling is not. Whereas this eliminates proteasome-dependent degradation of IkBα, other pathways of protein degradation may be involved. Therefore, we determined whether new protein synthesis is required to sustain the cytoplasmic localization of RELA by treating cells with the protein synthesis inhibitor cycloheximide. There was no translocation of RELA to
the nucleus within the time frame of our assays (data not shown), so the degradation-resynthesis mechanism of RELA/IκB cycling can be eliminated.

To distinguish between the remaining mechanisms, we examined the effect of free IκBα on the nuclear translocation of RELA in LMB-treated cells. If the basis of the translocation is dissociation, then increasing the concentration of free IκBα should reduce the rate of translocation because it will compete with the nuclear import machinery for free NFκB. It is not possible to obtain a direct measurement of free cytoplasmic IκBα, but it can be inferred from the nuclear IκBα concentration because NFκB-bound IκBα is predominantly cytoplasmic, whereas free IκBα distributes between the nucleus and cytoplasm in a 2:1 ratio. Furthermore, by using ECFP-RELA plus IκBα-EYFP-transfected cells we can both measure the nuclear translocation rate of RELA and estimate the relative concentration of free cytoplasmic IκBα. Performing this experiment with cells expressing increasing amounts of IκBα-EYFP, we
found that those cells with the highest level of nuclear iκB expression showed a reduced rate of ECFP-RELA import (Fig. 6). We do not believe this is due to competition between iκB and NFκB at the nuclear pore, because the expression levels are within the linear range of LMB-induced nuclear accumulation (Figs. 1 and 2). Therefore we conclude that the basis for the nuclear-cytoplasmic shuttling is dissociation of the NFκB-iκB dimer within the cytoplasm and independent import of the subunits into the nucleus.

The theoretical validity of this dissociation/reassociation mechanism hinges on the dynamics of NFκB-iκB interactions within the cell. We have previously estimated the intracellular concentration of RELA to be 50 nM (60,000 molecules per cell; volume, 2,000 μm³) (18). The dissociation constant of iκB for various NFκB dimers has also been determined; the strongest interaction (3 nM) occurred with the RELA-p50 heterodimer (23). If we assume that NFκB is predominantly present as a RELA-p50 heterodimer and that iκB is present in a small excess, then we predict that ~17% of cellular NFκB is free of iκB (by substitution into the equation \[ \text{[NFκB]} \cdot \text{[iκB]} = K_d \cdot \text{[NFκB-iκB]} \]). The presence of so much free NFκB was unexpected, so we examined how the predicted pool of free NFκB varies if the concentration and \( K_d \) estimates are modified (Fig. 7). We have previously estimated that the ratio of nuclear:cytoplasmic concentration is 1:10 and that the ratio of their volumes is also 1:10. Therefore, if the predominant function of iκB is to retain NFκB in the cytoplasm by masking of its nuclear translocation signal, it would be necessary to have no more than 1% uncomplexed NFκB. To obtain a level of free NFκB this low, the estimated concentration/dissociation constant would have to be incorrect by at least 50-fold (Fig. 7).

We have considered a simple equilibrium process above, but the actual percentage of free NFκB will be determined by the dynamic equilibrium established between the association/dissociation of NFκB-iκB complexes, the import of free subunits into the nucleus, and the export of associated complexes to the cytoplasm. We propose that rapid export of NFκB-iκB complexes from the nucleus is necessary to maintain the low nuclear concentration of NFκB due to the non-saturated interaction between NFκB and iκB. To investigate the theoretical validity of this mechanism of NFκB-iκB function and better understand the proposed dynamic regulation of NFκB distribution, we developed a model based upon it. Essentially, our model considers two processes: association and dissociation of the NFκB-iκB complexes and import and export of the individual subunits and of the complex from the cytoplasm to the nucleus (Fig. 8). We have investigated whether the model can account for the nuclear:cytoplasmic distribution of

---

**Fig. 5.** Simultaneous analysis of ECFP-RELA and iκBα-EYFP localization. A, nuclear import following treatment with LMB (10 ng/ml) is not blocked in the presence of the proteasome inhibitor MG132 (50 μM). B, nuclear import of ECFP-RELA and degradation of iκBα-EYFP following treatment with IL-1β (1 nM) are blocked in the presence of MG132 (50 μg/ml). ▲, nuclear ECFP-RELA; ○, cytoplasmic ECFP-RELA; △, nuclear iκBα-EYFP; ●, cytoplasmic iκBα-EYFP.

**Fig. 6.** Variation in the relative rate of ECFP-RELA nuclear import following LMB (10 ng/ml) treatment according to initial nuclear iκBα-EYFP expression level. Cells were transfected with pECFP-RELA plus pκBαEYFP, and cells with increasing concentrations of nuclear (free) iκBα-EYFP were analyzed. The initial distribution of ECFP-RELA is predominantly cytoplasmic in all the cells analyzed, whereas that of iκBα-EYFP varies from predominantly cytoplasmic to predominantly nuclear as its expression level increases.

**Fig. 7.** Free NFκB according to level of expression. The expected percentage of free cytoplasmic NFκB, in the absence of nuclear-cytoplasmic shuttling, is shown at \( K_d \) values for the NFκB-iκB complex of 30 (○), 10 (×), 3 (△), 1 (○), and 0.3 nM (□).
NFκB using the reported concentration of RELA and affinity constant for interaction with IκB. We found that two parameters are critical, namely the rate of import of IκB and export of the NFκB-IκB complex (Fig. 9A) and that, provided these are high enough, the model correctly simulates the distribution. Importantly, the underlying role of IκB is in part to inhibit the nuclear translocation of NFκB and in part to facilitate its nuclear export; neither alone is sufficient. The predictions generated by the model correlate with our experimental results, with one exception; the relative translocation rate predicted at increasing NFκB expression levels is markedly more concentration-dependent than that of the experimental observations (Fig. 9B). This difference might be explained in two ways. First, it could also be a consequence of exhaustion of the endogenous p50 subunits, resulting in the formation of lower affinity complexes of IκB with EGFP-RELA homodimers (Kd = 82 nM (23)). Alternatively, the off rate for the NFκB-IκB complex may be lower than the estimate we used, which would also be in accord with the ability to readily detect complexes by methods such as immunoprecipitation following cell lysis.

Whereas the dynamic model we are proposing is fundamentally very similar to the currently accepted static model, there are potentially important functional differences. First, the free nuclear NFκB concentration increases more gradually as IκB becomes sub-stoichiometric to NFκB, potentially facilitating graded, as opposed to on/off, activation of NFκB (Fig. 9C). This might have implications for the expression of certain genes at low levels of NFκB activation, in particular the regulation of basal IκB expression. Second, alterations of the dynamics of the NFκB-IκB interaction can have a pronounced impact on free nuclear NFκB levels (Fig. 9D). This might be important in the differential regulation of NFκB by alternate members of the IκB gene family or by stimuli that modify IκB without resulting in its degradation.

**DISCUSSION**

Much attention is currently being focused on understanding the process of signal transduction in mammalian cells. This work has resulted in the elucidation of a number of pathways, such as the IL-1/NFκB pathway studied in this report. To fully understand how these pathways function, we believe it is necessary to develop numerical models that accurately reflect their properties, and we have therefore used modelling to examine the consistency of our data with the suggested mechanism. Currently, our model is limited to the unstimulated partitioning of NFκB/IκB, but this core can be elaborated to model their redistribution following signal-induced modification/degradation of IκB. Whereas it is true that without exact knowledge of the parameter values the model is only a “guess,” useful insights can still be gained, and the parameters needing to be measured can be better defined.

One aspect common to many characterized signal transduction pathways is the involvement of sequentially acting kinases. These steps each have the potential for significant amplification, suggesting that the complete pathway may be subject to a large degree of amplification. However, our previous work has identified a modest limiting rate for nuclear translocation of EGFP-RELA that we suggested may either be
due to limitations in the signal transduction pathway or the NFκB nuclear import process. The present data substantiate the conclusion that the limitation is at or upstream of IκBα degradation and not a consequence of limitations on the rate of nuclear import of free NFκB.

Our experiments, in accord with other recent reports (24, 25), demonstrate that the cytoplasmic localization of NFκB in resting cells is not static but instead the result of balancing fluxes into and out of the nucleus. We demonstrate that the underlying cause for basal RELA and IκBα nuclear-cytoplasmic shuttling is the dissociation of IκBα-NFκB complexes as opposed to their direct nuclear import or degradation and resynthesis of IκBα. This mechanism is consistent with the previously determined affinity of the IκBα-NFκB interaction, which predicts sequestration of ~83% of NFκB dimers into inactive complexes. Without the nuclear export function of IκBα, the potential activation of NFκB following IκBα degradation is approximately 6-fold. However, the combined action of IκB-dependent nuclear export and formation of inactive complexes gives much lower residual nuclear activity and hence much more stringent regulation.

Because nuclear import and export are energy-dependent processes, the futile cycle of NFκB import to and export from the nucleus would appear to be energetically inefficient. Why should the system be designed in this manner when, with a higher affinity of interaction between IκB and NFκB, nuclear-cytoplasmic shuttling would be unnecessary? With two inhibitory steps (export and anchoring), the activity is more sensitive to small changes in the extent of interaction because the inhibition is proportional to the square of IκB-bound NFκB. If the binding between two molecules is near saturation, a small change in the affinity constant would have negligible effects on their free concentrations; however, under conditions of lower saturation, the same change can have a greater influence on the degree of interaction. This might be important in the differential interaction of the various NFκB dimers with specific IκBs. By keeping the dissociation constant high, specificity of inhibition can be better achieved.

Association/dissociation of the inhibitor may also allow for alteration in the nature of the complexes under different growth conditions or following transient activation of the inflammatory response. For example, following activation of NFκB, the synthesis of IκBα is induced. Hence, shortly after inactivation there may be a predominance of inhibitory complexes containing IκBα that are subsequently displaced by other inhibitors. This change may coincide with either greater or lesser sensitivity to specific inducing agents. In addition, it has been reported that IκBα is controlled under some circumstances by tyrosine phosphorylation, which results in dissociation but not degradation (13, 26). As discussed above, this mechanism is more tenable if the affinity of the complex is relatively low. Similar to the results reported here, recent analysis of the interaction of the glucocorticoid receptor with DNA has demonstrated rapid exchange between bound and free pools within living cells (27). Therefore, dynamic interactions involving transcription factors are probably common within living cells.

In conclusion, we propose that the regulation of NFκB is dependent on dynamic shuttling between the nucleus and cytoplasm and that underlying this shuttling is dissociation of the transcription factor and inhibitor within the cytoplasm. The numerical model we have developed accurately simulates many aspects of the nuclear-cytoplasmic distribution of NFκB but identifies areas of inconsistency for future research. Whereas it is well established that IκBα expression is induced by RELA overexpression, determination of precisely how the expression level of IκBα relates to the level of RELA is important to refine our model. Elaboration of the model to consider different NFκB dimers and other IκBs is also necessary but can only be achieved following characterization of their kinetics of interaction. Finally, direct measurement of the rate of nuclear import and export of specific complexes will also be required.

Acknowledgments—We thank the Immunex Corporation (Seattle, Washington) for the gift of IL-1β and Minoru Yoshida (Department of Biotechnology, University of Tokyo) for the gift of LMB.

REFERENCES

1. Verma, I. M., Stevenson, J. K., Schwarz, E. M., Vanantwerp, D., and Miyamoto, S. (1995) Genes Dev. 9, 2723–2735
2. Ghosh, S., May, M. J., and Kopp, E. B. (1998) Annu. Rev. Immunol. 16, 225–260
3. Bouras, V., Franszoo, G., Azarenko, V., Park, S., Kanno, T., Brown, K., and Siebenlist, U. (1993) Cell 72, 729–739
4. Fujita, T., Nolan, G. P., Liou, H. C., Scott, M. L., and Baltimore, D. (1993) Genes Dev. 7, 1534–1563
5. Beg, A., and Baldwin, A. S. (1993) Genes Dev. 7, 2064–2070
6. Baeuerle, P. A., and Baltimore, D. (1988) Science 242, 540–546
7. Jacobs, M. D., and Harrison, S. C. (1998) Cell 95, 749–758
8. Sen, R., and Baltimore, D. (1987) Cell 47, 921–928
9. Osborn, L., Kunkel, S., and Nabel, G. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2336–2340
10. Beg, A. A., Fineo, T. S., Nantermet, P. V., and Baldwin, A. S. (1993) Mol. Cell. Biol. 13, 3301–3310
11. Traenckner, E., Pahl, H., Henkel, T., Schmidt, K., Wilt, S., and Baeuerle, P. (1995) EMBO J. 14, 2876–2883
12. Henkel, T., Machleidt, T., Alkalay, I., Kronke, M., Ben-Neriah, Y., and Baeuerle, P. (1993) Nature 363, 182–185
13. Imbert, V., Rupee, R. A., Livolsi, A., Pahl, H. L., Traenckner, E. B. M., Mueller-Dieckmann, C., Farahifar, D., Rossi, B., Auburger, P., Baeuerle, P. A., and Peyron, J. F. (1996) Cell 86, 797–798
14. Wang, D., and Baldwin, A. S. (1998) J. Biol. Chem. 273, 29411–29416
15. Zhong, H., SuYang, H., Erdjument-Bromage, H., Tempst, P., and Ghosh, S. (1997) Cell 89, 413–424
16. Bergmann, M., Hart, L., Lindsay, M., Barnes, P., and Newton, R. (1998) J. Biol. Chem. 273, 6607–6610
17. Bird, T. A., Schooley, K., Dower, S. K., Hagen, H., and Virea, G. D. (1997) J. Biol. Chem. 272, 32606–32612
18. Carliotti, F., Chapman, R., Dower, S. K., and Qwarnstrom, E. E. (1999) J. Biol. Chem. 274, 37941–37949
19. Kudo, N., Kchobinh, S., Nishi, K., Kitano, K., Yanagida, M., Yoshida, M., and Horinouchi, S. (1997) J. Biol. Chem. 272, 29742–29751
20. Rodriguez, M. S., Thompson, J., Hay, R. T., and Dargemont, C. (1999) J. Biol. Chem. 274, 9108–9115
21. Chiao, P. J., Miyamoto, S., and Verma, I. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 28–32
22. Sun, S. C., Ganchi, P. A., Ballard, D. W., and Greene, W. C. (1993) Science 259, 1912–1915
23. Malek, S., Huxford, T., and Ghosh, G. (1993) J. Biol. Chem. 268, 25427–25435
24. Huang, T. T., Kudo, N., Yoshida, M., and Miyamoto, S. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 1014–1019
25. Johnson, C., Van Antwerp, D., and Hope, T. J. (1999) EMBO J. 18, 6682–6693
26. Chu, Z.-A., McKinsey, T. A., Liu, L., Qi, X., and Ballard, D. W. (1998) Mol. Cell. Biol. 16, 5974–5984
27. McNally, J. G., Muller, W. G., Walker, D., Wolford, R., and Hager, G. L. (2000) Science 287, 1262–1265